Kyverna Therapeutics, Inc. (KYTX) Stock Score, Valuation & Financial Research

Kyverna Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KYTX

Kyverna Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.16. These figures are a research snapshot, not a buy or sell recommendation.

What Kyverna Therapeutics, Inc. does

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kyverna Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its proprietary cell therapy pipeline for autoimmune diseases.

Products and services

  • The company is developing mivocabtagene autoleucel (miv-cel/KYV-101), an autologous, fully human CD19-targeting CAR T-cell therapy designed to deplete B cells in patients with autoimmune diseases.

Customer types

Academic institutions conducting investigator-initiated trials; Patients with autoimmune diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of its clinical trial materials and product candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • National Institutes of Health (NIH) — The company licenses the underlying chimeric antigen receptor (CAR) construct used in its lead product candidate, miv-cel, from the NIH. Source
  • Intellia Therapeutics, Inc. — A collaboration to develop KYV-201, an allogeneic CD19 CAR T-cell product candidate using gene editing technology. Source

Business strengths to evaluate

  • Proprietary miv-cel CAR construct with potential for differentiated therapeutic profile Source
  • Extensive clinical experience treating over 100 autoimmune patients Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KYTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.16
Market capitalization:
374.5M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -152.64M
Free cash flow:
USD -153.72M
Cash:
USD 31.81M
Total debt:
USD 33M
EPS:
USD -2.94

What stands out

  • Free cash flow is USD -153.72M, negative for the stored period.
  • The balance sheet shows USD 31.81M of cash versus USD 33M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 1.19M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KYTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KYTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does KYTX's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for KYTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of KYTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research KYTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.